The IL-23 inhibitor from AbbVie indicated for the treatment of adults with
active psoriatic arthritis (PsA) and for moderate to severe plaque psoriasis (Ps)
in adults who are candidates for systemic therapy or phototherapy.1
US-MULT-230356
US-MULT-230356
The IL-23 inhibitor from AbbVie indicated for the treatment of adults with
active psoriatic arthritis (PsA) and for moderate to severe plaque psoriasis (Ps)
in adults who are candidates for systemic therapy or phototherapy.1
SKYRIZI VS STELARA® (ustekinumab)1,2*
HEAD-TO-HEAD EFFICACY AT WEEK 16 IN 2 PIVOTAL PHASE 3
STUDIES OF PATIENTS WITH Ps
UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate Phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control (45 mg or 90 mg, based on screening weight) over 52 weeks in adult patients with moderate to severe plaque psoriasis.1,2
EFFICACY ENDPOINTS (P<0.0001)1,2
NRI=Non-responder imputation.
Co-primary endpoints were PASI 90 and sPGA 0/1 response vs placebo at Week 16. Secondary endpoints included PASI 90 and sPGA 0/1 response vs STELARA* and PASI 100 response vs placebo and STELARA at Week 16.1,2
The ustekinumab used as a biologic active control in UltIMMa-1 and UltIMMa-2 was sourced from the European Union. Comparability between non–US-approved ustekinumab and US-approved ustekinumab has not been established.
STELARA is a registered trademark of Johnson & Johnson. See US Prescribing Information for further information.
UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control (45 mg or 90 mg, based on screening weight) over 52 weeks in adult patients with moderate to severe plaque psoriasis.1,2
The ustekinumab used as a biologic active control in UltIMMa-1 and UltIMMa-2 was sourced from the European Union. Comparability between non–US-approved ustekinumab and US-approved ustekinumab has not been established.
STELARA is a registered trademark of Johnson & Johnson. See US Prescribing Information for further information.
In an open-label extension
KEY VARIABLES MEASURED EVERY 12 WEEKS THROUGH OLE5,6:
sPGA 0/1, sPGA 0, PASI 75, PASI 90, and PASI 100
Following completion of the RCT period, patients on blinded STELARA were switched to open-label SKYRIZI.4
LIMITATIONS:
In an open-label extension, there is potential for enrichment of the long-term data in the remaining patient populations since patients who are unable to tolerate or do not respond to the drug often drop out.
*ACTIVE COMPARATOR
The ustekinumab used as a biologic active control in UltIMMa-1 and UltIMMa-2 was sourced from the European Union. Comparability between non–US-approved ustekinumab and US-approved ustekinumab has not been established.
STELARA is a registered trademark of Johnson & Johnson. See US Prescribing Information for further information.
INTEGRATED RESULTS FROM ULTIMMA-1 & -2 PATIENTS (LOCF)
KEY VARIABLES MEASURED EVERY 12 WEEKS THROUGH OLE5,6:
sPGA 0/1, sPGA 0, PASI 75, PASI 90, and PASI 100
Following completion of the RCT period, patients on blinded STELARA were switched to open-label SKYRIZI.4
LIMITATIONS:
In an open-label extension, there is potential for enrichment of the long-term data in the remaining patient populations since patients who are unable to tolerate or do not respond to the drug often drop out.
*ACTIVE COMPARATOR
The ustekinumab used as a biologic active control in UltIMMa-1 and UltIMMa-2 was sourced from the European Union. Comparability between non–US-approved ustekinumab and US-approved ustekinumab has not been established.
STUDY DESIGN:
The randomized controlled trial data shown here are integrated results from UltIMMa-1 and -2. The open-label extension (OLE) data are a sub-analysis of LIMMitless and include only patients from UltIMMa-1 and -2 who completed the RCT and then enrolled in the OLE. LIMMitless is an OLE for which patients who completed either UltIMMa trial, IMMhance, or IMMvent were eligible to participate.4,5,7,8
STELARA is a registered trademark of Johnson & Johnson. See US Prescribing Information for further information.
LOCF=Last observation carried forward; OLE=Open-label extension; RCT=Randomized controlled trial.
In the randomized controlled trial and open-label extension
KEY VARIABLES MEASURED EVERY 12 WEEKS THROUGH OLE5,6:
sPGA 0/1, sPGA 0, PASI 75, PASI 90, and PASI 100
Following completion of the RCT period, patients on blinded STELARA were switched to open-label SKYRIZI.4
LIMITATIONS:
In an open-label extension, there is potential for enrichment of the long-term data in the remaining patient populations since patients who are unable to tolerate or do not respond to the drug often drop out.
*ACTIVE COMPARATOR
The ustekinumab used as a biologic active control in UltIMMa-1 and UltIMMa-2 was sourced from the European Union. Comparability between non–US-approved ustekinumab and US-approved ustekinumab has not been established.
STELARA is a registered trademark of Johnson & Johnson. See US Prescribing Information for further information.
INTEGRATED RESULTS FROM ULTIMMA-1 & -2 PATIENTS (LOCF)
KEY VARIABLES MEASURED EVERY 12 WEEKS THROUGH OLE5:
sPGA 0/1, sPGA 0, PASI 75, PASI 90, and PASI 100
Following completion of the RCT period, patients on blinded STELARA were switched to open-label SKYRIZI.4
LIMITATIONS:
In an open-label extension, there is potential for enrichment of the long-term data in the remaining patient populations since patients who are unable to tolerate or do not respond to the drug often drop out.
*ACTIVE COMPARATOR
The ustekinumab used as a biologic active control in UltIMMa-1 and UltIMMa-2 was sourced from the European Union. Comparability between non–US-approved ustekinumab and US-approved ustekinumab has not been established.
STUDY DESIGN:
The randomized controlled trial data shown here are integrated results from UltIMMa-1 and -2. The open-label extension (OLE) data are a sub-analysis of LIMMitless and include only patients from UltIMMa-1 and -2 who completed the RCT and then enrolled in the OLE. LIMMitless is an OLE for which patients who completed either UltIMMa trial, IMMhance, or IMMvent were eligible to participate.4,5,7,8
STELARA is a registered trademark of Johnson & Johnson. See US Prescribing Information for further information.
LOCF=Last observation carried forward; OLE=Open-label extension; RCT=Randomized controlled trial.
In an open-label extension
KEY VARIABLES MEASURED EVERY 12 WEEKS THROUGH OLE5,6:
sPGA 0/1, sPGA 0, PASI 75, PASI 90, and PASI 100
Following completion of the RCT period, patients on blinded STELARA were switched to open-label SKYRIZI.4
LIMITATIONS:
In an open-label extension, there is potential for enrichment of the long-term data in the remaining patient populations since patients who are unable to tolerate or do not respond to the drug often drop out.
*ACTIVE COMPARATOR
The ustekinumab used as a biologic active control in UltIMMa-1 and UltIMMa-2 was sourced from the European Union. Comparability between non–US-approved ustekinumab and US-approved ustekinumab has not been established.
STELARA is a registered trademark of Johnson & Johnson. See US Prescribing Information for further information.
INTEGRATED RESULTS FROM ULTIMMA-1 & -2 PATIENTS (LOCF)
KEY VARIABLES MEASURED EVERY 12 WEEKS THROUGH OLE5,8:
sPGA 0/1, sPGA 0, PASI 75, PASI 90, and PASI 100
Following completion of the RCT period, patients on blinded STELARA were switched to open-label SKYRIZI.
LIMITATIONS:
In an open-label extension, there is potential for enrichment of the long-term data in the remaining patient populations since patients who are unable to tolerate or do not respond to the drug often drop out.
*ACTIVE COMPARATOR
The ustekinumab used as a biologic active control in UltIMMa-1 and UltIMMa-2 was sourced from the European Union. Comparability between non–US-approved ustekinumab and US-approved ustekinumab has not been established.
STUDY DESIGN:
The randomized controlled trial data shown here are integrated results from UltIMMa-1 and -2. The open-label extension (OLE) data are a sub-analysis of LIMMitless and include only patients from UltIMMa-1 and -2 who completed the RCT and then enrolled in the OLE. LIMMitless is an OLE for which patients who completed either UltIMMa trial, IMMhance, or IMMvent were eligible to participate.4,5,7,8
STELARA is a registered trademark of Johnson & Johnson. See US Prescribing Information for further information.
LOCF=Last observation carried forward; OLE=Open-label extension; RCT=Randomized controlled trial.
In the randomized controlled trial and open-label extension
KEY VARIABLES MEASURED EVERY 12 WEEKS THROUGH OLE5,6:
sPGA 0/1, sPGA 0, PASI 75, PASI 90, and PASI 100
Following completion of the RCT period, patients on blinded STELARA were switched to open-label SKYRIZI.4
LIMITATIONS:
In an open-label extension, there is potential for enrichment of the long-term data in the remaining patient populations since patients who are unable to tolerate or do not respond to the drug often drop out.
*ACTIVE COMPARATOR
The ustekinumab used as a biologic active control in UltIMMa-1 and UltIMMa-2 was sourced from the European Union. Comparability between non–US-approved ustekinumab and US-approved ustekinumab has not been established.
STELARA is a registered trademark of Johnson & Johnson. See US Prescribing Information for further information.
INTEGRATED RESULTS FROM ULTIMMA-1 & -2 PATIENTS (LOCF)
KEY VARIABLES MEASURED EVERY 12 WEEKS THROUGH OLE5:
sPGA 0/1, sPGA 0, PASI 75, PASI 90, and PASI 100
Following completion of the RCT period, patients on blinded STELARA were switched to open-label SKYRIZI.4
LIMITATIONS:
In an open-label extension, there is potential for enrichment of the long-term data in the remaining patient populations since patients who are unable to tolerate or do not respond to the drug often drop out.
*ACTIVE COMPARATOR
The ustekinumab used as a biologic active control in UltIMMa-1 and UltIMMa-2 was sourced from the European Union. Comparability between non–US-approved ustekinumab and US-approved ustekinumab has not been established.
STUDY DESIGN:
The randomized controlled trial data shown here are integrated results from UltIMMa-1 and -2. The open-label extension (OLE) data are a sub-analysis of LIMMitless and include only patients from UltIMMa-1 and -2 who completed the RCT and then enrolled in the OLE. LIMMitless is an OLE for which patients who completed either UltIMMa trial, IMMhance, or IMMvent were eligible to participate.4,5,7,8
STELARA is a registered trademark of Johnson & Johnson. See US Prescribing Information for further information.
LOCF=Last observation carried forward; OLE=Open-label extension; RCT=Randomized controlled trial.
Well-Studied Safety Profile
across 4 pivotal trials1
4 DOSES PER YEAR
4 doses per year after 2 initiation doses at Weeks 0 and 4 (150 mg/dose)1
Psoriatic Arthritis: SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults.
Plaque Psoriasis: SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Important Safety Information
Hypersensitivity Reactions
SKYRIZI® (risankizumab-rzaa) is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately.
Infection
SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.
In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.
Tuberculosis (TB)
Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
Hepatotoxicity in Treatment of Crohn’s Disease
Drug-induced liver injury was reported in a patient with Crohn’s disease who was hospitalized for a rash during induction dosing of SKYRIZI. For the treatment of Crohn’s disease, evaluate liver enzymes and bilirubin at baseline and during induction (12 weeks); monitor thereafter according to routine patient management. Consider an alternate treatment for patients with evidence of liver cirrhosis. Interrupt treatment if drug-induced liver injury is suspected, until this diagnosis is excluded. Instruct your patient to seek immediate medical attention if they experience symptoms suggestive of hepatic dysfunction.
Administration of Vaccines
Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating SKYRIZI, complete all age-appropriate vaccinations according to current immunization guidelines.
Adverse Reactions
Most common (≥1%) adverse reactions associated with SKYRIZI in plaque psoriasis and psoriatic arthritis include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.
In psoriatic arthritis phase 3 trials, the incidence of hepatic events was higher with SKYRIZI compared to placebo.
Most common (>3%) adverse reactions associated with SKYRIZI in Crohn’s disease are upper respiratory infections, headache, and arthralgia in induction and arthralgia, abdominal pain, injection site reactions, anemia, pyrexia, back pain, arthropathy, and urinary tract infection in maintenance.
Lipid Elevations: Increases from baseline and increases relative to placebo were observed at Week 4 and remained stable to Week 12 in patients treated with SKYRIZI in Crohn’s disease.
Dosage Forms and Strengths: SKYRIZI is available in a 150 mg/mL prefilled syringe and pen, and a 600 mg/10 mL single-dose vial for intravenous infusion.
Please see Full Prescribing Information.
US-SKZG-220547
REFERENCES
US-SKZD-210080
IMMvent was a Phase 3, randomized, double-blind, double-dummy, active-controlled study to evaluate the efficacy and safety of SKYRIZI (150 mg) compared to HUMIRA® (adalimumab) in adult patients with moderate to severe plaque psoriasis over 44 weeks.
Patients treated with adalimumab during Part A:
Part A
In the first phase, patients were randomized 1:1 to either SKYRIZI (150 mg), given as a subcutaneous injection at Weeks 0 and 4 and every 12 weeks thereafter or HUMIRA, given as a subcutaneous injection, with an initial dose of 80 mg followed by 40 mg every other week starting 1 week after the initial dose over 44 weeks.
The Part A co-primary endpoints were
Part B
Patients originally randomized to SKYRIZI received it throughout the study (Parts A & B). Among patients originally randomized to receive HUMIRA, those with a PASI 50 but less than PASI 90 response were re-randomized 1:1 to switch to SKYRIZI or continue HUMIRA.
The Part B primary endpoint was
Key secondary endpoints included
Key inclusion criteria
OLE=Open-Label Extension
PASI=Psoriasis Area and Severity Index
PASI 90=≥90% improvement in Psoriasis Area and Severity Index
PASI 100=100% improvement in Psoriasis Area and Severity Index
Q2W=Once every 2 weeks
sPGA=static Physician's Global Assessment
Click to see HUMIRA® (adalimumab) Indication and Important Safety Information, including BOXED WARNING for Serious Infections and Malignancy
OLE=Open-Label Extension
PASI=Psoriasis Area and Severity Index
PASI 90=≥90% improvement in Psoriasis Area and Severity Index
PASI 100=100% improvement in Psoriasis Area and Severity Index
Q2W=Once every 2 weeks
sPGA=static Physician's Global Assessment
REFERENCE
ADA=Adalimumab
BSA=Body Surface Area
PASI=Psoriasis Area and Severity Index
PsA=Psoriatic Arthritis
RZB=Risankizumab-rzaa
TNFi=Tumor Necrosis Factor Inhibitor
REFERENCES
US-SKZR-220084
IMMerge was a Phase 3, global, multicenter, randomized, open-label, efficacy–assessor-blinded, active-comparator study that evaluated the safety and efficacy of SKYRIZI 150 mg vs COSENTYX 300 mg in moderate to severe plaque psoriasis subjects, who were candidates for systemic therapy.
The primary endpoints were
Ranked secondary endpoints (all superiority)
Key inclusion criteria
Sourcing
In this study, 46 patients outside of the US received non–US-licensed secukinumab.
Data regarding comparability between US and non-US secukinumab are not publicly available.
BSA=Body Surface Area
PASI=Psoriasis Area and Severity Index
sPGA=static Physician's Global Assessment
REFERENCE
BSA=Body Surface Area
PASI=Psoriasis Area and Severity Index
RZB=Risankizumab-rzaa
SEC=Secukinumab
sPGA=static Physician's Global Assessment
aMean baseline body weight was 92 kg in the secukinumab group and 91.1 kg in the risankizumab group.2
bStratification factors at randomization.
REFERENCES
US-SKZR-220084
IMMhance was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the impact of treatment withdrawal and re-treatment of SKYRIZI compared to placebo in adult patients with moderate to severe plaque psoriasis.
Part A
In the first phase, patients were randomized 4:1 to SKYRIZI (150 mg), given as a subcutaneous injection at baseline, 4 weeks later, and every 12 weeks thereafter, or placebo.
The Part A co-primary endpoints were
Part B
In the second phase of this study (Week 28 through Week 104), patients originally randomized to SKYRIZI who achieved sPGA 0/1 at Week 28 were re-randomized (1:2) to SKYRIZI (maintenance) or placebo (withdrawal). Beginning at Week 32, patients with sPGA ≥2 continued on SKYRIZI (150 mg) once every 12 weeks up to Week 88, with a final follow-up at Week 104.
The Part B primary endpoint was
Key inclusion criteria
Key secondary endpoints included
DLQI=Dermatology Life Quality Index
OLE=Open-Label Extension
PASI=Psoriasis Area and Severity Index
PASI 75=≥75% improvement in Psoriasis Area and Severity Index
PASI 90=≥90% improvement in Psoriasis Area and Severity Index
PASI 100=100% improvement in Psoriasis Area and Severity Index
Q12W=Once every 12 weeks
sPGA=static Physician's Global Assessment
REFERENCES
BSA=Body Surface Area
PASI=Psoriasis Area and Severity Index
PBO=Placebo
PsA=Psoriatic Arthritis
RZB=Risankizumab-rzaa
TNFi=Tumor Necrosis Factor Inhibitor
aStratification factors at randomization.
REFERENCES
US-SKZR-220084
UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate Phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control (45 mg or 90 mg, based on screening weight) over 52 weeks in adult patients with moderate to severe plaque psoriasis. SKYRIZI (150 mg) was given as 2 subcutaneous injections at Weeks 0, 4, 16, 28, and 40. Patients were randomized 3:1:1 to receive SKYRIZI, ustekinumab, or placebo. At Week 16, patients on placebo were switched to SKYRIZI.
LIMMitless is an ongoing, single-arm, multicenter, open-label extension study evaluating the long-term efficacy and safety of SKYRIZI (150 mg). Patients who completed UltIMMa-1 or -2, IMMvent, or IMMhance were eligible to participate.
Active comparator
The active comparator (ustekinumab) used for these studies was sourced from the European Union.
OLE=Open-Label Extension
PASI=Psoriasis Area and Severity Index
PASI 90=≥90% improvement in Psoriasis Area and Severity Index
PASI 100=100% improvement in Psoriasis Area and Severity Index
sPGA=static Physician's Global Assessment
The co-primary endpoints were
Key secondary endpoints included
Key inclusion criteria
OLE=Open-Label Extension
PASI=Psoriasis Area and Severity Index
PASI 90=≥90% improvement in Psoriasis Area and Severity Index
PASI 100=100% improvement in Psoriasis Area and Severity Index
sPGA=static Physician's Global Assessment
REFERENCES
BSA=Body Surface Area
PASI=Psoriasis Area and Severity Index
PBO=Placebo
PsA=Psoriatic Arthritis
RZB=Risankizumab-rzaa
TNFi=Tumor Necrosis Factor Inhibitor
UST=Ustekinumab
aStratification factors at randomization.
REFERENCE
US-SKZR-220084
US-SKZD-220459
UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate Phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control (45 mg or 90 mg, based on screening weight) over 52 weeks in adult patients with moderate to severe plaque psoriasis. SKYRIZI (150 mg) was given as 2 subcutaneous injections at Weeks 0, 4, 16, 28, and 40. Patients were randomized 3:1:1 to receive SKYRIZI, ustekinumab, or placebo. At Week 16, patients on placebo were switched to SKYRIZI.
Active comparator
The active comparator (ustekinumab) used for these studies was sourced from the European Union.
The co-primary endpoints were
Key secondary endpoints included
Key inclusion criteria
OLE=Open-Label Extension
PASI=Psoriasis Area and Severity Index
PASI 90=≥90% improvement in Psoriasis Area and Severity Index
PASI 100=100% improvement in Psoriasis Area and Severity Index
sPGA=static Physician's Global Assessment
REFERENCES
BSA=Body Surface Area
PASI=Psoriasis Area and Severity Index
PBO=Placebo
PsA=Psoriatic Arthritis
RZB=Risankizumab-rzaa
TNFi=Tumor Necrosis Factor Inhibitor
UST=Ustekinumab
aStratification factors at randomization.
REFERENCE:
US-SKZR-220084
UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate Phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control (45 mg or 90 mg, based on screening weight) over 52 weeks in adult patients with moderate to severe plaque psoriasis. SKYRIZI (150 mg) was given as 2 subcutaneous injections at Weeks 0, 4, 16, 28, and 40. Patients were randomized 3:1:1 to receive SKYRIZI, ustekinumab, or placebo. At Week 16, patients on placebo were switched to SKYRIZI.
Active comparator
The active comparator (ustekinumab) used for these studies was sourced from the European Union.
The co-primary endpoints were
Key secondary endpoints included
Key inclusion criteria
OLE=Open-Label Extension
PASI=Psoriasis Area and Severity Index
PASI 90=≥90% improvement in Psoriasis Area and Severity Index
PASI 100=100% improvement in Psoriasis Area and Severity Index
sPGA=static Physician's Global Assessment
REFERENCES
BSA=Body Surface Area
PASI=Psoriasis Area and Severity Index
PBO=Placebo
PsA=Psoriatic Arthritis
RZB=Risankizumab-rzaa
TNFi=Tumor Necrosis Factor Inhibitor
UST=Ustekinumab
aStratification factors at randomization.
REFERENCE:
US-SKZR-220084
US-SKZ-220108
US-SKZ-220107
KEEPsAKE 1: csDMARD-IR. KEEPsAKE 2: Mixed population (50% csDMARD-IR, 50% Bio-IR)
KEEPsAKE 1 (N=964) and KEEPsAKE 2 (N=443) were 2 randomized, double-blind, placebo-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 24 weeks with an open-label extension for up to an additional 204 weeks in adult patients with active psoriatic arthritis.
In both studies, patients were randomized to receive SKYRIZI 150 mg or placebo at Weeks 0, 4, and 16. Starting from Week 28, all patients received SKYRIZI every 12 weeks. 59.6% of patients from both studies were receiving concomitant MTX, 11.6% were receiving concomitant non-biologic DMARDs other than MTX, and 28.9% were receiving SKYRIZI monotherapy.
Patients in KEEPsAKE 1 previously experienced an inadequate response, intolerance, or contraindication to ≥1 csDMARD. Patients in KEEPsAKE 2 were bio-IR and/or csDMARD-IR.
In both studies, similar responses were seen regardless of concomitant non-biologic DMARD use, number of prior non-biologic DMARDs, age, gender, race, and BMI. In KEEPsAKE 2, responses were seen regardless of prior biologic therapy.
*The first n-value is for KEEPsAKE 1; the second n-value is for KEEPsAKE 2.
†At Week 16, patients classified as nonresponders (defined as not achieving at least a 20% improvement in either or both tender joint count and swollen joint count at both Week 12 and Week 16 compared to baseline) had the option to add or modify rescue concomitant medications/therapy. Starting at Week 36, patients classified as nonresponders were discontinued from study drug.
‡To maintain the blind to the original treatment at Week 24, patients randomized to placebo received blinded risankizumab 150 mg, and patients randomized to risankizumab received blinded placebo.
Primary endpoint
Select ranked secondary endpoints
Non-ranked secondary endpoints
Key inclusion criteria
ACR=American College of Rheumatology
Bio-IR=inadequate response or intolerance to a biologic
BMI=body mass index
csDMARD=conventional synthetic disease-modifying antirheumatic drugs
csDMARD-IR=intolerance or inadequate response to conventional synthetic disease-modifying antirheumatic drug(s)
LDI=Leeds Dactylitis Index
LEI=Leeds Enthesitis Index
mTSS=modified total Sharp Score
MTX=methotrexate
NRI-C=non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19
OLE=open-label extension
PASI=Psoriasis Area Severity Index
PBO=placebo
RZB=risankizumab-rzaa
aAmong patients with ≥3% body surface area affected by psoriasis at baseline.
bNot included in KEEPsAKE 2.
cAmong patients with nail psoriasis at baseline.
dDefined as LEI=0 among patients with LEI >0 at baseline. Prespecified analysis of pooled data from the KEEPsAKE 1 and KEEPsAKE 2 trials (RZB, n=444; PBO, n=448).
eDefined as LDI=0 among patients with LDI >0 at baseline. Prespecified analysis of pooled data from the KEEPsAKE 1 and KEEPsAKE 2 trials (RZB, n=188; PBO, n=204).
REFERENCES
aBased on 68 joints.
bBased on 66 joints.
BMI=body mass index
BSA=body surface area
csDMARD=conventional synthetic disease-modifying antirheumatic drugs
mTSS=modified Total Sharp Score
MTX=methotrexate
NSAID=nonsteroidal anti-inflammatory drug
PBO=placebo
PsA=psoriatic arthritis
RZB=risankizumab-rzaa
BMI=body mass index
BSA=body surface area
csDMARD=conventional synthetic disease-modifying antirheumatic drugs
mTSS=modified Total Sharp Score
MTX=methotrexate
NSAID=nonsteroidal anti-inflammatory drug
PBO=placebo
PsA=psoriatic arthritis
RZB=risankizumab-rzaa
REFERENCES
US-SKZR-220084
US-SKZR-220084
To achieve an ACR20, 50, or 70 response, a patient must have at least a 20%, 50%, or 70%, respectively, improvement in tender and swollen joint counts and three of five scores of individual elements:
REFERENCES
1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc. 2. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(suppl II):ii49-ii54. 3. Data on file, AbbVie Inc. ABVRRTI71868. 4. Mease P, Strand V, Gladman D. Functional impairment measurement in psoriatic arthritis: importance and challenges. Semin Arthritis Rheum. 2018;48(3):436-448.
US-SKZR-220084
Click to see HUMIRA® (adalimumab) Indication and Important Safety Information, including
BOXED WARNING for Serious Infections and Malignancy. See Full Prescribing Information.
ACTIVE COMPARATOR
The ustekinumab used as a biologic active control in UltIMMa-1 and UltIMMa-2 was sourced from the European Union. Comparability between non–US-approved ustekinumab and US-approved ustekinumab has not been established. See Full Prescribing Information for US-approved ustekinumab, which reflects different rates of adverse events from those observed for EU-approved ustekinumab in the UltIMMa trials.
Safety analyses were performed using a safety analysis set (all patients who received ≥1 dose of study drug). No safety data for adalimumab or placebo were obtained beyond Week 16.
aIncludes data from UltIMMa-1, UltIMMa-2, IMMhance, and IMMvent studies.
bIncludes data from UltIMMa-1, UltIMMa-2, and Phase 2 study 1311.2.
cSKYRIZI (150 mg), adalimumab, and placebo were only evaluated in Phase 3 trials; the ustekinumab group includes Phase 3 patients (N=199) in addition to Phase 2 patients (n=40).
dIncludes data from IMMvent study.
eIncludes data from UltIMMa-1, UltIMMa-2, and IMMhance studies.
IBD=inflammatory bowel disease; MACE=major adverse cardiovascular event; NMSC=nonmelanoma skin cancer; Ps=psoriasis; TB=tuberculosis.
STELARA is a registered trademark of Johnson & Johnston. See US prescribing information for further information.
REFERENCES
US-SKZR-220084
Active Comparator
The ustekinumab used as a biologic active control in UltIMMa-1 and UltIMMa-2 was sourced from the European Union. Comparability between non–US-approved ustekinumab and US-approved ustekinumab has not been established. See Full Prescribing Information for US-approved ustekinumab, which reflects different rates of adverse events from those observed for EU-approved ustekinumab in the UltIMMa trials.
Safety analyses were performed using a safety analysis set (all patients who received ≥1 dose of study drug). No safety data for adalimumab or placebo were obtained beyond Week 16.
aIncludes data from UltIMMa-1 and UltIMMa-2 studies.
STELARA is a registered trademark of Johnson & Johnson. See US Prescribing Information for further information.
REFERENCES
US-SKZR-220084
*The first n-value is for KEEPsAKE 1; the second n-value is for KEEPsAKE 2.
†At Week 16, subjects classified as nonresponders (defined as not achieving at least a 20% improvement in either or both tender joint count and swollen joint count at both Week 12 and Week 16 compared to baseline) had the option to add or modify rescue concomitant medications/therapy. Starting at Week 36, subjects classified as nonresponders were discontinued from study drug.
‡To maintain the blind to the original treatment at Week 24 subjects randomized to placebo received blinded SKYRIZI 150 mg, and subjects randomized to SKYRIZI received blinded placebo.
KEEPsAKE 1: csDMARD-IR. KEEPsAKE 2: Mixed population (~50% csDMARD-IR, ~50% Bio-IR)
csDMARD-IR population: Inadequate response (lack of efficacy after minimum 12-week duration of therapy) or intolerance to previous or current treatment with at least 1 csDMARD at maximally tolerated dose; Bio-IR population: Inadequate response (lack of efficacy after minimum 12-week duration of therapy) or intolerance to treatment with 1 or 2 biologic therapies intended to treat PsA
KEEPsAKE 1 (N=964) and KEEPsAKE 2 (N=443) were 2 randomized, double-blind, placebo-controlled studies that evaluated the efficacy and safety of SKYRIZI (150 mg) vs placebo over 24 weeks with an open-label extension for up to an additional 204 weeks in adult patients with active psoriatic arthritis.
In both studies, subjects were randomized to receive SKYRIZI 150 mg or placebo at Weeks 0, 4 and 16. Starting at Week 28, all subjects received SKYRIZI every 12 weeks. 59.6% of subjects from both studies received concomitant MTX, 11.6% received concomitant nonbiologic DMARDs other than MTX, and 28.9% received SKYRIZI monotherapy.
In both studies, similar responses were seen regardless of concomitant nonbiologic DMARD use, number of prior nonbiologic DMARDs, age, gender, race, and BMI.
In KEEPsAKE 2, responses were seen regardless of prior biologic therapy.
In KEEPsAKE 1, bilateral radiographs of hands and feet were included at screening, baseline, Week 24, Week 52, and Week 100.
Primary endpoint
Ranked key secondary endpoints
Non-ranked secondary endpoints
Key inclusion criteria
aIn the subset of subjects with a body surface area (BSA) ≥3% at baseline.
bIn the subset of subjects with nail psoriasis at baseline.
cIn the subset of subjects with enthesitis at the LEI sites at baseline.
dIn the subset of subjects with dactylitis at the LDI sites at baseline.
ACR=American College of Rheumatology; ACR20=improvement of at least 20% in tender joint count, swollen joint count, and at least 3 other core criteria; ACR50=improvement of at least 50% in tender joint count, swollen joint count, and at least 3 other core criteria; ACR70=improvement of at least 70% in tender joint count, swollen joint count, and at least 3 other core criteria; Bio-lR=inadequate response or intolerance to a biologic; BMI=body mass index; csDMARD=conventional synthetic disease-modifying antirheumatic drugs; csDMARD-IR=intolerance or inadequate response to conventional synthetic disease-modifying antirheumatic drugs; DMARD=disease-modifying antirheumatic drug; HAQ-Dl=health assessment questionnaire disability index; LDI=Leeds Dactylitis Index; LEI=Leeds Enthesitis Index; MDA=minimal disease activity; mNAPSl=modified Nail Psoriasis Severity Index; MTX=methotrexate; OLE=open-label extension; PASI 90=≥90% improvement in Psoriasis Area and Severity Index; PsA=psoriatic arthritis.
REFERENCES
aBased on 68 joints.
bBased on 66 joints.
BMI=body mass index; BSA=body surface area; csDMARD=conventional synthetic disease-modifying antirheumatic drug; DMARD=disease-modifying antirheumatic drugs; HAQ-DI=health assessment questionnaire disability index; LDI=Leeds Dactylitis Index; LEI=Leeds Enthesitis Index; mTSS=modified total Sharp score; MTX=methotrexate; NSAIDs=nonsteroidal anti-inflammatory drugs; PASl=Psoriasis Area and Severity Index; PsA=psoriatic arthritis.
REFERENCES
US-SKZR-220180
